2023 Exhibitors Search
Guilver Biomed
Exhibit Item |
Bio · Medical · Pharma
|
---|---|
Country | Belgium |
Tel (Rep.) | +32-475333218 |
Website | http://https://gulliverbiomed.com |
Company Introduction
Antibodies have tremendous impact in the clinic, in diagostics and in research. Nanobodies (discovered in Belgium) are small 15 kDa antibodies with huge potential in diagnostics and therapeutics. They surpass conventional IgGs.
Nanobody cDNA is always available, economizing recombinant production. We derivatize nanobodies for site-specific ADC development, for generating nuclear tracers, coupling to biologicals.
Clinical trials with nanobodies are ongoing in the context of CAR-T, chimeric antigen receptor T cell therapy. They are also emerging in the context of vaccine development. Nanobodies are an ideal stepping stone towards drug development. They 'scan' the surface of a target protein and detect sensitive/druggable regions in proteins. An ideal instrument against ‘undruggable’ targets.
Gulliver Biomed is your partner for nanobody development against any protein. 40 research papers published, > 15 years experience. Technology transfer possible.
Nanobody cDNA is always available, economizing recombinant production. We derivatize nanobodies for site-specific ADC development, for generating nuclear tracers, coupling to biologicals.
Clinical trials with nanobodies are ongoing in the context of CAR-T, chimeric antigen receptor T cell therapy. They are also emerging in the context of vaccine development. Nanobodies are an ideal stepping stone towards drug development. They 'scan' the surface of a target protein and detect sensitive/druggable regions in proteins. An ideal instrument against ‘undruggable’ targets.
Gulliver Biomed is your partner for nanobody development against any protein. 40 research papers published, > 15 years experience. Technology transfer possible.
Promotional Video
Exhibit Item
Unicorn technology. Gulliver Biomed develops llama single domain antibodies/VHHs for use as research tool, diagnostic, therapeutic. We welcome research projects, joint development of new pharmaceuticals, CAR-T antibodies, use in mRNA vaccins. Nanobodies display very broad applicability and are stable in the cytoplasm of cells unlike IgGs. We are interested in collaborative projects, participation in research projects, joint development of new pharmaceuticals or antibody drug conjugates, VHHs, intrabodies.
Exhibit Description
Phage panning
Nanobody derivitization
VHH library construction
Affinity determination
Epitope mapping
Nanobody purification
Intrabody expression
Antigen expression and purification
Nanobody derivitization
VHH library construction
Affinity determination
Epitope mapping
Nanobody purification
Intrabody expression
Antigen expression and purification
Co-Exhibitor or
Partner’s Information
Company Name | Country | Website |
---|